Related Experiment Video

Updated: May 22, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Pirarubicin inhibits multidrug-resistant osteosarcoma cell proliferation through induction of G2/M phase cell cycle

Shui-er Zheng1, Sang Xiong, Feng Lin

  • 1Department of Oncology, Affiliated People's 6th Hospital, Shanghai Jiao Tong University, China.

Acta Pharmacologica Sinica
|May 15, 2012
PubMed
Abstract

Insights

Pirarubicin (THP) effectively treats multidrug-resistant (MDR) osteosarcoma cells by halting cell cycle progression at the G(2)/M phase. This mechanism explains THP

Area of Science:

  • Oncology
  • Cell Biology
  • Pharmacology

Background:

  • High-grade osteosarcoma, particularly advanced, relapsed, or recurrent cases, presents significant treatment challenges.
  • Multidrug resistance (MDR) in osteosarcoma limits the efficacy of conventional chemotherapies like doxorubicin and gemcitabine.

Purpose of the Study:

  • To evaluate the effects of pirarubicin (THP) on multidrug-resistant (MDR) osteosarcoma cells.
  • To investigate the mechanisms by which THP disrupts cell cycle kinetics in MDR osteosarcoma.

Main Methods:

  • Utilized human osteosarcoma (MG63) and MDR osteosarcoma (MG63/DOX) cell lines.
  • Assessed drug cytotoxicity using Cell Counting Kit-8 (CCK-8) assays.
  • Determined cell cycle distribution via flow cytometry and analyzed cell cycle-related protein expression (cyclin B1, Cdc2, Cdc25C) using Western blot.

Main Results:

  • MG63/DOX cells exhibited resistance to doxorubicin and gemcitabine but sensitivity to THP.
  • THP inhibited MG63/DOX cell proliferation and induced G(2)/M phase cell cycle arrest in a dose- and time-dependent manner.
  • THP downregulated cyclin B1 and p-Cdc2 (Thr161), while upregulating p-Cdc2 (Thr14/Tyr15) and p-Cdc25C (Ser216), decreasing Cdc2-cyclin B1 activity.

Conclusions:

  • Pirarubicin demonstrates significant cytotoxicity against MDR osteosarcoma cells.
  • THP-induced G(2)/M phase cell cycle arrest is a key mechanism underlying its efficacy.
  • These findings support the potential use of THP in managing patients with multidrug-resistant osteosarcoma.

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...